181 related articles for article (PubMed ID: 22147077)
1. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
2. H2-receptor antagonist influences dasatinib pharmacokinetics in a patient with Philadelphia-positive acute lymphoblastic leukemia.
Matsuoka A; Takahashi N; Miura M; Niioka T; Kawakami K; Matsunaga T; Sawada K
Cancer Chemother Pharmacol; 2012 Aug; 70(2):351-2. PubMed ID: 22678358
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects.
Eley T; Luo FR; Agrawal S; Sanil A; Manning J; Li T; Blackwood-Chirchir A; Bertz R
J Clin Pharmacol; 2009 Jun; 49(6):700-9. PubMed ID: 19395585
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation.
Takahashi N; Miura M; Scott SA; Niioka T; Sawada K
J Hematol Oncol; 2012 May; 5():23. PubMed ID: 22587422
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
7. Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Yokota H; Sato K; Okuda Y; Kobayashi H; Takeda M; Asano M; Ito H; Miura M
Clin Lung Cancer; 2017 Nov; 18(6):e433-e439. PubMed ID: 28579188
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Thappali SR; Varanasi KV; Veeraraghavan S; Vakkalanka SK; Khagga M
Arzneimittelforschung; 2012 Dec; 62(12):624-30. PubMed ID: 23138519
[TBL] [Abstract][Full Text] [Related]
9. Four-day continuous gastric pH monitoring following anti-acid secretory drug administration: cross-over test to assess the early effects.
Suzuki T; Yamaguchi T; Odaka T; Kobayashi M; Seza A; Kouzu T; Yokosuka O
Aliment Pharmacol Ther; 2008 Jan; 27(1):66-71. PubMed ID: 17922801
[TBL] [Abstract][Full Text] [Related]
10. Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Dai G; Pfister M; Blackwood-Chirchir A; Roy A
J Clin Pharmacol; 2008 Nov; 48(11):1254-69. PubMed ID: 18779376
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and absorption of the anticancer agents dasatinib and GDC-0941 under various gastric conditions in dogs--reversing the effect of elevated gastric pH with betaine HCl.
Pang J; Dalziel G; Dean B; Ware JA; Salphati L
Mol Pharm; 2013 Nov; 10(11):4024-31. PubMed ID: 23980865
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
[TBL] [Abstract][Full Text] [Related]
14. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
16. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
Koutake Y; Taniguchi J; Yasumori N; Nagaishi H; Eto T; Nakashima K; Fukazawa M; Hayashi T
Int J Hematol; 2020 Jun; 111(6):826-832. PubMed ID: 32152877
[TBL] [Abstract][Full Text] [Related]
17. Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3.
Narumi K; Sato Y; Kobayashi M; Furugen A; Kasashi K; Yamada T; Teshima T; Iseki K
Biopharm Drug Dispos; 2017 Dec; 38(9):501-508. PubMed ID: 28801980
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
20. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
